Arfolitixorin Emerging Drug Insight

“Arfolitixorin Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Arfolitixorin for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the Arfolitixorin for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the Arfolitixorin for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Arfolitixorin market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard-of-care chemotherapy for advanced CRC. As the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin, arfolitixorin can potentially benefit all patients with advanced CRC, as it does not require complicated metabolic activation to become effective. Folic acid is converted by the human body into a pool of at least six interconvertible forms of reduced folates. Among the various metabolites involved, the active ingredient contained in arfolitixorin plays the most crucial role as the last reduced folate in the chain, which functions as a substrate for the TS enzyme.

When treating CRC, arfolitixorin is administered in combination with 5-FU to increase cell mortality in circulating cancer cells and in cancerous tumors. Arfolitixorin is administered in conjunction with rescue therapy after high-dose treatment with the cytotoxic agent, methotrexate, to suppress the cytotoxic effect in surrounding healthy tissue. The treatment is used for certain types of cancer, such as osteosarcoma, a type of bone cancer; this involves administering arfolitixorin separately, 24 hours after the chemotherapy.

In August 2020, Isofol entered into a license agreement with Solasia Pharma to develop and commercialize Isofol’s proprietary late-stage drug candidate, arfolitixorin, in Japan. Isofol retains rights to arfolitixorin in the rest of the world. The company had earlier entered into a global, exclusive supply and licensing agreement with Merck KGaA and Merck & Co. for the development and commercialization of arfolitixorin in cancer treatment.

The drug candidate is currently being studied in a global Phase III study, AGENT (NCT03750786), in combination with bevacizumab for the treatment of advanced colorectal cancer (1L).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Arfolitixorin description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Arfolitixorin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Arfolitixorin research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Arfolitixorin.
• The report contains forecasted sales of Arfolitixorin for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Arfolitixorin in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Arfolitixorin Analytical Perspective by DelveInsight

In-depth Arfolitixorin Market Assessment

This report provides a detailed market assessment of Arfolitixorin in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Arfolitixorin Clinical Assessment

The report provides the clinical trials information of Arfolitixorin in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Arfolitixorin dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Arfolitixorin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Arfolitixorin in Metastatic Colorectal Cancer.
• Our in-depth analysis of the forecasted sales data of Arfolitixorin from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Arfolitixorin in Metastatic Colorectal Cancer.

Key Questions

• What is the product type, route of administration, and mechanism of action of Arfolitixorin?
• What is the clinical trial status of the study related to Arfolitixorin in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the Arfolitixorin development?
• What are the key designations that have been granted to Arfolitixorin for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Arfolitixorin for Metastatic Colorectal Cancer?
• What are the forecasted sales of Arfolitixorin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Arfolitixorin for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?